Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study

Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3–6 months. New treatment modalities are thus urgently needed. Telomerase is expressed in 85–90% of pancreas cancer, and immunogenic telomerase peptides have been characterised. A phase I/II study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernhardt, S L, Gjertsen, M K, Trachsel, S, Møller, M, Eriksen, J A, Meo, M, Buanes, T, Gaudernack, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360729/
https://www.ncbi.nlm.nih.gov/pubmed/17060934
http://dx.doi.org/10.1038/sj.bjc.6603437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360729/
https://www.ncbi.nlm.nih.gov/pubmed/17060934
http://dx.doi.org/10.1038/sj.bjc.6603437

Ejemplares similares